Potential of Nutraceuticals against Obesity Complications
| dc.contributor.author | Conroy, Kylie | |
| dc.contributor.author | Davidson, Isobel | |
| dc.contributor.author | Warnock, Mary | |
| dc.contributor.editor | Mahabir, Somdat | |
| dc.contributor.editor | Pathak, Yashwant | |
| dc.date.accessioned | 2018-06-29T21:33:42Z | |
| dc.date.available | 2018-06-29T21:33:42Z | |
| dc.date.issued | 2013 | |
| dc.description.abstract | Obesity has been regarded as a disease by the World Health Organisation (WHO) since its inception in 1948; however, it was not deemed a public health problem by WHO until 1997 (James 2008). The most widely used method of classifying overweight and obesity is by body mass index (BMI = weight/ height2), and those with a BMI of 25-29.99 kg/m2 are classified as overweight and those with a BMI of ≥30 kg/m2 as obese (WHO 2011). However, although BMI correlates with body fat it is not a direct measure and results may be skewed by a high muscle mass such as can be seen in some athletes. | |
| dc.description.eprintid | 3347 | |
| dc.description.faculty | sch_die | |
| dc.description.ispublished | pub | |
| dc.description.status | pub | |
| dc.format.extent | 133-151 | |
| dc.identifier | ER3347 | |
| dc.identifier.citation | Conroy, K., Davidson, I. and Warnock, M. (2013) ‘Potential of nutraceuticals against obesity complications’, in Nutraceuticals and Health. CRC Press. | |
| dc.identifier.isbn | 978 1 4665 1722 6 | |
| dc.identifier.uri | https://eresearch.qmu.ac.uk/handle/20.500.12289/3347 | |
| dc.publisher | CRC Press | |
| dc.relation.ispartof | Nutraceuticals and Health - Review of Human Evidence | |
| dc.title | Potential of Nutraceuticals against Obesity Complications | |
| dc.type | book_section | |
| dcterms.accessRights | none | |
| qmu.author | Warnock, Mary | |
| qmu.author | Davidson, Isobel | |
| rioxxterms.publicationdate | 2013 | |
| rioxxterms.type | book_section |